<- Go Home
OncoZenge AB (publ)
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.
Market Cap
SEK 114.8M
Volume
57.0K
Cash and Equivalents
SEK 7.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
SEK 4.0K
Profit Margin
100.00%
52 Week High
SEK 12.10
52 Week Low
SEK 2.30
Dividend
N/A
Price / Book Value
8.08
Price / Earnings
-9.73
Price / Tangible Book Value
15.59
Enterprise Value
SEK 107.2M
Enterprise Value / EBITDA
N/A
Operating Income
-SEK 11.8M
Return on Equity
59.44%
Return on Assets
-34.44
Cash and Short Term Investments
SEK 7.6M
Debt
N/A
Equity
SEK 14.2M
Revenue
SEK 4.0K
Unlevered FCF
-SEK 8.8M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium